Mu opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers.
paper
Cited
Public
Unavailable
- Authors
- Drakenberg, Katarina; Nikoshkov, Andrej; HorvΓ‘th, Monika Cs; Fagergren, Pernilla; Gharibyan, Anna; Saarelainen, Kati; Rahman, Sadia; Nylander, Ingrid; Bakalkin, Georgy; Rajs, Jovan; Keller, Eva; Hurd, Yasmin L
- Year
- 2006
- Journal
- Proceedings of the National Academy of Sciences of the United States of America
- PMID
- 16682632
- DOI
- 10.1073/pnas.0600871103
- PMCID
- PMC1472539
Mu opioid receptors are critical for heroin dependence, and A118G SNP of the mu opioid receptor gene (OPRM1) has been linked with heroin abuse. In our population of European Caucasians (n = 118), approximately 90% of 118G allelic carriers were heroin users. Postmortem brain analyses showed the OPRM1 genotype associated with transcription, translation, and processing of the human striatal opioid neuropeptide system. Whereas down-regulation of preproenkephalin and preprodynorphin genes was evident in all heroin users, the effects were exaggerated in 118G subjects and were most prominent for preproenkephalin in the nucleus accumbens shell. Reduced opioid neuropeptide transcription was accompanied by increased dynorphin and enkephalin peptide concentrations exclusively in 118G heroin subjects, suggesting that the peptide processing is associated with the OPRM1 genotype. Abnormal gene expression related to peptide convertase and ubiquitin/proteosome regulation was also evident in heroin users. Taken together, alterations in opioid neuropeptide systems might underlie enhanced opiate abuse vulnerability apparent in 118G individuals.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| A GWAS Meta-meta-analysis and In-depth Silico Pharmacogenomic Investigations in Identification of APOE and Other Genes Associated with Pain, Anti-inflammatory, and Immunomodulating Agents in Opioid Use Disorder (OUD) Derived from 14.91 M Subjects. | Sharafshah A et al. | β | 2025 | β |
| Neuropeptide receptors as entry points for developmental vulnerability to drug abuse. | Harkany T et al. | β | 2025 | β |
| Neuropeptides: The Evergreen Jack-of-All-Trades in Neuronal Circuit Development and Regulation. | Hevesi Z et al. | β | 2025 | β |
| OPRM1 Gene Polymorphism in Women with Alcohol Use Disorder. | BoroΕ A et al. | β | 2024 | β |
| Solving the Global Opioid Crisis: Incorporating Genetic Addiction Risk Assessment with Personalized Dopaminergic Homeostatic Therapy and Awareness Integration Therapy. | Zeine F et al. | β | 2024 | β |
| A Brief Overview of the Neuropharmacology of Opioid Addiction. | Grothusen JR et al. | β | 2022 | β |
| Dysregulated expression of the alternatively spliced variant mRNAs of the mu opioid receptor gene, OPRM1, in the medial prefrontal cortex of male human heroin abusers and heroin self-administering male rats. | Brown TG et al. | β | 2022 | β |
| Knock-In Mouse Models to Investigate the Functions of Opioid Receptors <i>in vivo</i>. | Degrandmaison J et al. | β | 2022 | β |
| The molecular neurobiology and neuropathology of opioid use disorder. | Blackwood CA et al. | β | 2021 | β |
| Chromatin accessibility mapping of the striatum identifies tyrosine kinase FYN as a therapeutic target for heroin use disorder. | Egervari G et al. | β | 2020 | β |
| Common schizophrenia risk variants are enriched in open chromatin regions of human glutamatergic neurons. | Hauberg ME et al. | β | 2020 | β |
| Haplotype-Based Association and In Silico Studies of OPRM1 Gene Variants with Susceptibility to Opioid Dependence Among Addicted Iranians Undergoing Methadone Treatment. | Tolami HF et al. | β | 2020 | β |
| Assessing the contribution of opioid- and dopamine-related genetic polymorphisms to the abuse liability of oxycodone. | Jones JD et al. | β | 2019 | β |
| Current understanding of the neurobiology of opioid use disorder: An overview. | Moningka H et al. | β | 2019 | β |
| Escalated Oxycodone Self-Administration and Punishment: Differential Expression of Opioid Receptors and Immediate Early Genes in the Rat Dorsal Striatum and Prefrontal Cortex. | Blackwood CA et al. | β | 2019 | β |
| HERCing: Structural and Functional Relevance of the Large HERC Ubiquitin Ligases. | GarcΓa-Cano J et al. | β | 2019 | β |
| Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders. | Burns JA et al. | β | 2019 | β |
| Molecular windows into the human brain for psychiatric disorders. | Egervari G et al. | β | 2019 | β |
| A unique role for DNA (hydroxy)methylation in epigenetic regulation of human inhibitory neurons. | Kozlenkov A et al. | β | 2018 | β |
| Downregulation of the neuronal opioid gene expression concomitantly with neuronal decline in dorsolateral prefrontal cortex of human alcoholics. | Bazov I et al. | β | 2018 | β |
| Dynorphin and ΞΊ-Opioid Receptor Dysregulation in the Dopaminergic Reward System of Human Alcoholics. | Bazov I et al. | β | 2018 | β |
| Heroin-induced suppression of saccharin intake in OPRM1 A118G mice. | Freet CS et al. | β | 2018 | β |
| Molecular Genetics and New Medication Strategies for Opioid Addiction. | Hurd YL et al. | β | 2018 | β |
| Oprm1 A112G, a single nucleotide polymorphism, alters expression of stress-responsive genes in multiple brain regions in male and female mice. | Collins D et al. | β | 2018 | β |
| Ventral striatal regulation of CREM mediates impulsive action and drug addiction vulnerability. | Miller ML et al. | β | 2018 | β |
| DNA Methylation Profiling of Human Prefrontal Cortex Neurons in Heroin Users Shows Significant Difference between Genomic Contexts of Hyper- and Hypomethylation and a Younger Epigenetic Age. | Kozlenkov A et al. | β | 2017 | β |
| Striatal H3K27 Acetylation Linked to Glutamatergic Gene Dysregulation in Human Heroin Abusers Holds Promise as Therapeutic Target. | Egervari G et al. | β | 2017 | β |
| A Functional 3'UTR Polymorphism (rs2235749) of Prodynorphin Alters microRNA-365 Binding in Ventral Striatonigral Neurons to Influence Novelty Seeking and Positive Reward Traits. | Egervari G et al. | β | 2016 | β |
| Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. | Schwantes-An TH et al. | β | 2016 | β |
| Morphine-induced antinociception and reward in "humanized" mice expressing the mu opioid receptor A118G polymorphism. | Henderson-Redmond AN et al. | β | 2016 | β |
| Opioids and social bonding: naltrexone reduces feelings of social connection. | Inagaki TK et al. | β | 2016 | β |
| Searching for evidence of genetic mediation of opioid withdrawal by opioid receptor gene polymorphisms. | Jones JD et al. | β | 2016 | β |
| Substantial DNA methylation differences between two major neuronal subtypes in human brain. | Kozlenkov A et al. | β | 2016 | β |
| Mouse model of OPRM1 (A118G) polymorphism has altered hippocampal function. | Mague SD et al. | β | 2015 | β |
| [Stabilization of remission in patients with opioid dependence with naltrexone implant: a pharmacogenetic approach]. | Krupitsky ΠΠ et al. | β | 2015 | β |
| A heroin addiction severity-associated intronic single nucleotide polymorphism modulates alternative pre-mRNA splicing of the ΞΌ opioid receptor gene OPRM1 via hnRNPH interactions. | Xu J et al. | β | 2014 | β |
| A unique gene expression signature associated with serotonin 2C receptor RNA editing in the prefrontal cortex and altered in suicide. | Di Narzo AF et al. | β | 2014 | β |
| Differences in DNA methylation between human neuronal and glial cells are concentrated in enhancers and non-CpG sites. | Kozlenkov A et al. | β | 2014 | β |
| Strain differences in the expression of endocannabinoid genes and in cannabinoid receptor binding in the brain of Lewis and Fischer 344 rats. | Coria SM et al. | β | 2014 | β |
| Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside? | Mura E et al. | β | 2013 | β |
| Dopamine receptor D1 and postsynaptic density gene variants associate with opiate abuse and striatal expression levels. | Jacobs MM et al. | β | 2013 | β |
| ELK1 transcription factor linked to dysregulated striatal mu opioid receptor signaling network and OPRM1 polymorphism in human heroin abusers. | Daws SE et al. | β | 2013 | β |
| Impaired periamygdaloid-cortex prodynorphin is characteristic of opiate addiction and depression. | Anderson SA et al. | β | 2013 | β |
| Kappa-opioid receptor signaling in the striatum as a potential modulator of dopamine transmission in cocaine dependence. | Trifilieff P et al. | β | 2013 | β |
| Low frequency genetic variants in the ΞΌ-opioid receptor (OPRM1) affect risk for addiction to heroin and cocaine. | Clarke TK et al. | β | 2013 | β |
| On the role of genetic testing for personalized drug overdose management. | Manini A et al. | β | 2013 | β |
| OPRM1 rs1799971 polymorphism and opioid dependence: evidence from a meta-analysis. | Haerian BS et al. | β | 2013 | β |
| Shared and unique genetic contributions to attention deficit/hyperactivity disorder and substance use disorders: a pilot study of six candidate genes. | Carpentier PJ et al. | β | 2013 | β |
| The endogenous opioid system in human alcoholics: molecular adaptations in brain areas involved in cognitive control of addiction. | Bazov I et al. | β | 2013 | β |
| Cannabis-dependence risk relates to synergism between neuroticism and proenkephalin SNPs associated with amygdala gene expression: case-control study. | Jutras-Aswad D et al. | β | 2012 | β |
| Genetic-epigenetic interaction modulates ΞΌ-opioid receptor regulation. | Oertel BG et al. | β | 2012 | β |
| Genetic factors modulating the response to stimulant drugs in humans. | Hart AB et al. | β | 2012 | β |
| Opiate drug use and the pathophysiology of neuroAIDS. | Hauser KF et al. | β | 2012 | β |
| The genetics of the opioid system and specific drug addictions. | Levran O et al. | β | 2012 | β |
| Zebrafish: a model for the study of addiction genetics. | Klee EW et al. | β | 2012 | β |
| A polymorphism of the CREB binding protein (CREBBP) gene is a risk factor for addiction. | Kumar D et al. | β | 2011 | β |
| Dysregulated postsynaptic density and endocytic zone in the amygdala of human heroin and cocaine abusers. | Okvist A et al. | β | 2011 | β |
| Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. | Ray R et al. | β | 2011 | β |
| Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. | Hung CC et al. | β | 2011 | β |
| No evidence of association between 118A>G OPRM1 polymorphism and heroin dependence in a large Bulgarian case-control sample. | Nikolov MA et al. | β | 2011 | β |
| OPRM1 gene variants modulate amphetamine-induced euphoria in humans. | Dlugos AM et al. | β | 2011 | β |
| Pharmacogenomics of the human Β΅-opioid receptor. | Kasai S et al. | β | 2011 | β |
| OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. | Mague SD et al. | β | 2010 | β |
| Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. | Yuferov V et al. | β | 2010 | β |
| Single-nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu-opioid receptor and may contribute to the genetic risk for addiction. | Deb I et al. | β | 2010 | β |
| uAUG-mediated translational initiations are responsible for human mu opioid receptor gene expression. | Song KY et al. | β | 2010 | β |
| Alterations of prodynorphin gene expression in the rat mesocorticolimbic system during heroin self-administration. | Solecki W et al. | β | 2009 | β |
| Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution. | Doehring A et al. | β | 2009 | β |
| Lack of association between the A118G polymorphism of the mu opioid receptor gene (OPRM1) and opioid dependence: A meta-analysis. | Coller JK et al. | β | 2009 | β |
| Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. | Mague SD et al. | β | 2009 | β |
| Progressive Purkinje cell degeneration in tambaleante mutant mice is a consequence of a missense mutation in HERC1 E3 ubiquitin ligase. | Mashimo T et al. | β | 2009 | β |
| Abnormal heat and pain perception in remitted heroin dependence months after detoxification from methadone-maintenance. | Prosser JM et al. | β | 2008 | β |
| Differential opioid action on sensory and affective cerebral pain processing. | Oertel BG et al. | β | 2008 | β |
| Differential regulation of prohormone convertase 1/3, prohormone convertase 2 and phosphorylated cyclic-AMP-response element binding protein by short-term and long-term morphine treatment: implications for understanding the "switch" to opiate addiction. | Espinosa VP et al. | β | 2008 | β |
| Genetic susceptibility to heroin addiction: a candidate gene association study. | Levran O et al. | β | 2008 | β |
| Opioid neuropeptide genotypes in relation to heroin abuse: dopamine tone contributes to reversed mesolimbic proenkephalin expression. | Nikoshkov A et al. | β | 2008 | β |
| Pharmacogenetic treatments for drug addiction: alcohol and opiates. | Haile CN et al. | β | 2008 | β |
| Targeting endogenous mu- and delta-opioid receptor systems for the treatment of drug addiction. | Shippenberg TS et al. | β | 2008 | β |
| The neural circuitry underlying reinstatement of heroin-seeking behavior in an animal model of relapse. | Rogers JL et al. | β | 2008 | β |
| A novel SNP detection technique utilizing a multiple primer extension (MPEX) on a phospholipid polymer-coated surface. | Imai K et al. | β | 2007 | β |
| Endogenous opiates and behavior: 2006. | Bodnar RJ | β | 2007 | β |
| Evaluation of OPRM1 variants in heroin dependence by family-based association testing and meta-analysis. | Glatt SJ et al. | β | 2007 | β |
| Neuroproteomics and its applications in research on nicotine and other drugs of abuse. | Li MD et al. | β | 2007 | β |
| Neuroproteomics and its applications in research on nicotine and other drugs of abuse. | Li MD et al. | β | 2007 | β |
| The opioid system in alcohol and drug dependence: family-based association study. | Xuei X et al. | β | 2007 | β |
| Perspectives on current directions in the neurobiology of addiction disorders relevant to genetic risk factors. | Hurd YL | β | 2006 | β |
| Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone. | Oslin DW et al. | β | 2006 | β |